Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Background: Academic medical centers are examining relationships with the pharmaceutical industry
and making changes to limit interactions. Most doctors, however, practice outside of academic institutions
and see pharmaceutical detailers and accept drug samples and gifts. Little guidance for practicing
physicians exists about transforming practices to become pharma-free. Consideration must be...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...
Background: Academic detailing is an interactive, convenient, and user-friendly approach to delivering non-commercial education to healthcare clinicians. While evidence suggests academic detailing is associated with improvements in prescribing behavior, uncertainty exists about generalizability and scalability in diverse settings. Our study evaluates different models of delivering academic detailing in a rural...
Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX)
may provide an advantage over other oral agents approved for alcohol and opioid dependence
treatment. The objective of this study was to evaluate cost and utilization outcomes between
XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence.
Published studies were...